Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.

MLA

Blanc, Jean-Frédéric, et al. “Phase 2 Trial Comparing Sorafenib, Pravastatin, Their Combination or Supportive Care in HCC with Child-Pugh B Cirrhosis.” Hepatology International, vol. 15, no. 1, Feb. 2021, pp. 93–104. EBSCOhost, https://doi.org/10.1007/s12072-020-10120-3.

APA

Blanc, J.-F., Khemissa, F., Bronowicki, J.-P., Monterymard, C., Perarnau, J.-M., Bourgeois, V., Obled, S., Abdelghani, M. B., Mabile-Archambeaud, I., Faroux, R., Seitz, J.-F., Locher, C., Senellart, H., Villing, A.-L., Audemar, F., Costentin, C., Deplanque, G., Manfredi, S., & Edeline, J. (2021). Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis. Hepatology International, 15(1), 93–104. https://doi.org/10.1007/s12072-020-10120-3

Chicago

Blanc, Jean-Frédéric, Faiza Khemissa, Jean-Pierre Bronowicki, Carole Monterymard, Jean-Marc Perarnau, Vincent Bourgeois, Stéphane Obled, et al. 2021. “Phase 2 Trial Comparing Sorafenib, Pravastatin, Their Combination or Supportive Care in HCC with Child-Pugh B Cirrhosis.” Hepatology International 15 (1): 93–104. doi:10.1007/s12072-020-10120-3.